{"title":"Google Scholar\u3067\"Mifepristone deleterious\"\u3092\u691c\u7d22\u3057\u305f\u7d50\u679c","provider_name":"Hatena Blog","version":"1.0","blog_title":"\u30ea\u30d7\u30ed\u306a\u65e5\u8a18","categories":[],"published":"2023-08-12 23:52:05","author_name":"okumi","url":"https://okumi.hatenablog.com/entry/2023/08/12/235205","description":"\u5c11\u306a\u304f\u3068\u3082\u6700\u521d\u306e10\u4ef6\u306b\u306f\u30df\u30d5\u30a7\u30d7\u30ea\u30b9\u30c8\u30f3\u306f\u5371\u967a\u3068\u3044\u3046\u5831\u544a\u306f1\u4ef6\u306e\u307f 1) [HTML] Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome D Jain - Journal of Mid-life Health, 2018 - ncbi.nlm.nih.gov \u2026 Leiomyomata causing symptoms have a deleterious effect on the health of women during rep\u2026","image_url":null,"width":"100%","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fokumi.hatenablog.com%2Fentry%2F2023%2F08%2F12%2F235205\" title=\"Google Scholar\u3067&quot;Mifepristone deleterious&quot;\u3092\u691c\u7d22\u3057\u305f\u7d50\u679c - \u30ea\u30d7\u30ed\u306a\u65e5\u8a18\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","type":"rich","provider_url":"https://hatena.blog","author_url":"https://blog.hatena.ne.jp/okumi/","height":"190","blog_url":"https://okumi.hatenablog.com/"}